Are Anuh Pharma latest results good or bad?

Anuh Pharma has reported its financial results for the quarter ending June 2025, which reflect several concerning operational trends. The company achieved net sales of Rs 384.62 crore, indicating a year-on-year growth of 27.44%. However, this figure represents a quarter-on-quarter decline of 5.88% compared to the previous quarter. Profit After Tax (PAT) for the quarter was Rs 8.30 crore, which is a significant decrease of 29.9% relative to the average PAT from the last four quarters. Additionally, the operating profit fell to Rs 10.30 crore, marking the lowest level in five quarters, with an operating profit margin of 5.52%. Profit Before Tax (PBT) also reached a low of Rs 7.56 crore, and earnings per share (EPS) decreased to Rs 0.83. The annual dividend per share (DPS) was reported at Rs 0.75, with a dividend payout ratio of 15.87%, the lowest in five years. Furthermore, the company saw an adjustment in its evaluation over the past three months, indicating a shift in its financial standing. Overall, the results suggest that while there was some growth in net sales year-on-year, the underlying operational metrics reveal significant challenges for Anuh Pharma in the recent quarter.